Cargando cotizaciones...
Previsión
No hay datos de analistas disponibles para esta empresa.
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Incannex Healthcare reports quarterly loss per share of $0.15
Incannex Healthcare reported earnings per share of -$0.15 for the quarter ended June 30, 2026, presented at the finance conference on September 25, 2026. For the fiscal year it reported a loss per share of -$1.66, after -$40.50 in the prior year. » Más en finanzen.net
Incannex Healthcare receives AUD 6.04m tax credit and expects a further AUD 5.1m
Incannex Healthcare has received a payment of AUD 6,039,162.43 from the Australian research and development incentive program and expects additional tax credits of AUD 5.1 million in 2026. The expected total proceeds from this non-dilutive capital therefore exceed AUD 11.1 million. The funds are intended to support further development of clinical programs such as IHL-42X and PSX-001 and capital allocation measures, including a share buyback program. » Más en de.investing.com
Incannex starts DReAMzz study to optimise dosing of IHL-42X for obstructive sleep apnea
Incannex has begun the clinical DReAMzz crossover study to optimise dosing of IHL-42X (dronabinol/acetazolamide) for the treatment of obstructive sleep apnea. The company lists 14 identified study centres, completed manufacturing of the investigational products, and secured import/export approvals and distribution agreements to activate the sites. IHL-42X has Fast Track status with the FDA; Incannex notes rapid cash burn despite positive balance-sheet metrics and says adequate funding is critical (market capitalization: $53.8m; share price: $3.90). » Más en de.investing.com
Incannex reactivates stock buyback program after pause
Incannex resumed its stock buyback program after a period of inactivity over the last two trading days and says it will opportunistically continue repurchasing shares. The biopharmaceutical company reports about $75 million in cash following a financing round, is debt-free and shows a very high short-term liquidity ratio (Current Ratio 48.27). The stock trades at $3.41, below the InvestingPro fair value of $4.06; as of 31.12.2025 roughly $18.5 million remained available for buybacks. Incannex stresses the decision reflects a discrepancy between market valuation and its financial position as well as progress in the clinical pipeline (including IHL-42X, PSX-001). » Más en de.investing.com
Incannex has about $75m in cash after financing round and is debt-free
Incannex has roughly $75 million in cash following a financing round led by institutional healthcare investors and carries no debt. Market capitalization is around $46 million, which together with the liquidity position results in a negative enterprise value. The proceeds are intended primarily to fund the phase‑2 dosing‑optimization study DReAMzz for IHL‑42X (obstructive sleep apnea); IHL‑42X has FDA Fast Track status. The company plans dose administrations in the coming months, has an approved share buyback program, and is concurrently advancing development of PSX‑001 (oral synthetic psilocybin). » Más en de.investing.com
Datos financieros de la empresa
| (EUR) | 2023 | YoY |
|---|---|---|
| Ingresos | 618,83 mil | 20,15 % |
| Beneficio bruto | 618,83 mil | 21,13 % |
| Beneficio neto | -12,19 M | 122,65 % |
| EBITDA | -10,79 M | 361,24 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 8,73 M € |
Número de acciones | 347,71 M |
Máximo/mínimo de 52 semanas | 0,17 € - 0,0251 € |
| Dividendos | No |
Beta | 2,09 |
Ratio P/E | -2,88 |
Ratio PEG | -0,03 |
Ratio P/B | 0,37 |
Ratio P/S | 0,00 |
Perfil de la empresa
Incannex Healthcare Limited se dedica a la investigación, el desarrollo y la venta de productos medicinales a base de cannabinoides en Australia. Ofrece productos de cannabinoides de calidad farmacéutica bajo la marca Incannex. Los productos de la empresa incluyen IHL-42X, que se encuentra en ensayos clínicos de fase II para la apnea obstructiva del sueño; IHL-216A para la lesión cerebral traumática; e IHL-675A, una combinación de hidroxicloroquina y cannabidiol para la prevención y el tratamiento de afecciones pulmonares inflamatorias, como el síndrome de dificultad respiratoria aguda, la enfermedad pulmonar obstructiva crónica, el asma y la bronquitis, así como la artritis reumatoide y las enfermedades inflamatorias intestinales. Tiene una alianza con The Alfred Hospital y Novotech para el programa clínico de IHL-42X para la apnea obstructiva del sueño; y con Monash Trauma Group, del Departamento de Neurociencia de la Universidad de Monash, para llevar a cabo un estudio sobre el efecto protector de IHL-216A en la conmoción cerebral deportiva. La empresa se conocía anteriormente como Impression Healthcare Limited y cambió su nombre a Incannex Healthcare Limited en junio de 2020. Incannex Healthcare Limited se constituyó en 2001 y tiene su sede en Sídney, Australia.
| Nombre | INCANNEX HEALTHCARE LTD. |
| CEO | Joel Bradley Latham |
| Sede | Sydney,
nsw Australia |
| Sitio web | |
| Salida a bolsa | 23/05/2007 |
| Empleados | 3 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
Australian Securities Exchange Ltd | IHL.AX |